

EPI Country Report

SURINAME, 2019



Demographics and socioeconomic

Total Population (in 1000) (2019)	581.36
Population <1 year of age (in 1000) (2019)	10.36
Population 1 year of age (in 1000)(2019)	10.44
Population <5 years of age (in 1000) (2019)	52.45
Women of childbearing age (2019)	300.22
Infant Mortality Rate (per 1000 live births) (2017)	14.02
Gross national income (US\$ per capita) current value (2018)	4,990.00
National Health Expenditure Public (2016)	4.21
National Health Expenditure Private (2016)	1.77

Immunization system highlights

- There is a comprehensive multi-year plan for immunization covering 2020-2025.
- A standing national technical advisory group on immunization (NITAG) The group met 3 times in 2019.
- 96% of spending on routine immunization is financed using government funds.
- 100% of spending on vaccine purchases is financed using government funds.
- A national nominal electronic immunization registry implementation is in progress.


Immunization Schedule

SUR	Doses					
	1	2	3	4	5	6
BCG						
HepB_Pediatric	1st contact					
DTP-Hib						
DTP-Hib-HepB	M2	M4	M6			
DTP-Hib-IPV						
DTP-Hib-HepB-IPV				M18	Y4-5	
DTP						
IPV	M2					
OPV		M4	M6	M18	Y4-5	
MMR	M12	M18				
Pneumoco_conj						
Rotavirus						
Td	1st contact	+6M	+1Y			
TdaP						
HPV	Y9					

Vaccine Introduction

	Year
Bacterial Meningitis	
<i>Haemophilus influenzae</i> type b	2005
Hepatitis B	2003
HPV	2013
Influenza	2009
MMR1	1993
MMR2	2005
Pentavalent	2005
Pneumococcal Conjugate	
Rotavirus	
Tdap	
Tetraivalent DPT-Hib or DPT-HepB	
Yellow Fever	2005

Vaccination Coverage



Surveillance Indicators - AFP (CARPHA)


	2019
Number od AFP suspected cases	8
AFP rate per 100,000 population <15 years old	0.57
% of cases with 1 adequate samples	100
% of cases investigated within <48 hours	100
% sites reporting	83

Surveillance Indicators - MR (CARPHA)


	2019
Number of suspected cases	371
% of cases with adequate investigation	86
% of cases with adequate blood samples	98
% of samples received in laboratory <=5 days	9
% of laboratory samples results <=4 days	83




Polio3 coverage and AFP rate per 100,000 children <15 years of age




DTP3 coverage and number of reported diphtheria and pertussis cases




Number of tetanus (no neonatal) and neonatal tetanus cases



Proportion of municipalities by coverage range with DTP3 in children <1 years of age



DTP1-DTP3 and DTP1-MMR1 Dropout Rate



Legend	
NB/nb-newborn	● with stockout
M/m -month	● no stockout
Y/y-year	● no data available
WCBA-women of childbearing age	

Vaccine Stockout

